TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy ...

Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive ...

Chen, D. and Li, L. (2025) Huge Pelvic GIST Got Good Control after Resistance to Tyrosine Kinase Inhibitors by SIB-IMRT: A ...

Equities research analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a report issued on Sunday. The firm set a “hold” rating on the stock ...

Cogent Biosciences (NASDAQ:COGT – Get Free Report) is projected to release its earnings data before the market opens on ...

E1s and E2s first work generically across the cell to activate and prepare ubiquitin for attachment. E3 ligases then ensure that the tag is added to the right protein; as such, hundreds of specific ...

The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Dr Annalisa Morgan previews discussions on disease-modifying therapies, emerging treatments such as CAR T-cell therapy, and ...

CSPC Megalith Biopharmaceutical has entered into a license agreement with Radiance Biopharma for the development and ...

FDA has granted priority review for Boehringer Ingelheim’s zongertinib NDA for treating unresectable or metastatic NSCLC.

Insulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high ...